dc.contributor.author
Lingscheid, Tilman
dc.contributor.author
Lippert, Lena J.
dc.contributor.author
Hillus, David
dc.contributor.author
Kruis, Tassilo
dc.contributor.author
Thibeault, Charlotte
dc.contributor.author
Helbig, Elisa T.
dc.contributor.author
Tober-Lau, Pinkus
dc.contributor.author
Pfäfflin, Frieder
dc.contributor.author
Müller-Redetzky, Holger
dc.contributor.author
Witzenrath, Martin
dc.contributor.author
Zoller, Thomas
dc.contributor.author
Uhrig, Alexander
dc.contributor.author
Opitz, Bastian
dc.contributor.author
Suttorp, Norbert
dc.contributor.author
Kramer, Tobias S.
dc.contributor.author
Sander, Leif E.
dc.contributor.author
Stegemann, Miriam S.
dc.contributor.author
Kurth, Florian
dc.date.accessioned
2024-09-11T13:16:41Z
dc.date.available
2024-09-11T13:16:41Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/44916
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-44626
dc.description.abstract
Purpose: To investigate antimicrobial use and primary and nosocomial infections in hospitalized COVID-19 patients to provide data for guidance of antimicrobial therapy.
Methods: Prospective observational cohort study conducted at Charite-Universitatsmedizin Berlin, including patients hospitalized with SARS-CoV-2-infection between March and November 2020.
Results: 309 patients were included, 231 directly admitted and 78 transferred from other centres. Antimicrobial therapy was initiated in 62/231 (26.8%) of directly admitted and in 44/78 (56.4%) of transferred patients. The rate of microbiologically confirmed primary co-infections was 4.8% (11/231). Although elevated in most COVID-19 patients, C-reactive protein and procalcitonin levels were higher in patients with primary co-infections than in those without (median CRP 110 mg/l, IQR 51-222 vs. 36, IQR 11-101, respectively; p < 0.0001). Nosocomial bloodstream and respiratory infections occurred in 47/309 (15.2%) and 91/309 (29.4%) of patients, respectively, and were associated with need for invasive mechanical ventilation (OR 45.6 95%CI 13.7-151.8 and 104.6 95%CI 41.5-263.5, respectively), extracorporeal membrane oxygenation (OR 14.3 95%CI 6.5-31.5 and 16.5 95%CI 6.5-41.6, respectively), and haemodialysis (OR 31.4 95%CI 13.9-71.2 and OR 22.3 95%CI 11.2-44.2, respectively). The event of any nosocomial infection was significantly associated with in-hospital death (33/99 (33.3%) with nosocomial infection vs. 23/210 (10.9%) without, OR 4.1 95%CI 2.2-7.3).
Conclusions: Primary co-infections are rare, yet antimicrobial use was frequent, mostly based on clinical worsening and elevated inflammation markers without clear evidence for co-infection. More reliable diagnostic prospects may help to reduce overtreatment. Rates of nosocomial infections are substantial in severely ill patients on organ support and associated with worse patient outcome.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Antimicrobial stewardship
en
dc.subject
Antimicrobial resistance
en
dc.subject
Bloodstream infections
en
dc.subject
Co-infection
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s15010-022-01796-w
dcterms.bibliographicCitation.journaltitle
Infection
dcterms.bibliographicCitation.number
6
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
1441
dcterms.bibliographicCitation.pageend
1452
dcterms.bibliographicCitation.volume
50
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35420370
dcterms.isPartOf.issn
0300-8126
dcterms.isPartOf.eissn
1439-0973